Bio-Techne $TECH up 20%; Merck agrees $11.3B cash deal
Original: Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets View original →
Bio-Techne $TECH rose about 20% to $70.70 on June 26 after Merck KGaA signed a cash deal to buy the Minneapolis life-sciences tools company for $73 a share, or about $11.3B in enterprise value. The price is 36% above Bio-Techne's one-month volume-weighted average trading price, according to the joint company release.
The transaction clears the crawler's Tier-1 M&A threshold because the agreed value is far above $500M and the target is a publicly traded S&P 500 supplier to biopharma, diagnostics, academic research, and cell-therapy manufacturing customers. Bio-Techne shareholders would receive cash rather than stock, while Merck plans to finance the acquisition with cash on hand and new debt while preserving an investment-grade credit rating.
The deal gives Merck a larger position in life-sciences workflows across multi-omics, spatial biology, protein analysis, analytical technologies, and consumables. Merck said Bio-Techne would add complementary assets across research, bioprocessing, and advanced therapeutics, with the combined platform expected to expand customer reach across North America, Europe, Asia-Pacific, and other markets.
The financial case rests on scale and cost savings. Merck expects about EUR 140M of annual cost synergies by year 3 after closing, immediate EBITDA pre-margin accretion after the transaction closes, and EPS pre accretion by year 3. The release also says the transaction has been approved by Bio-Techne's board and Merck's relevant corporate bodies.
The next checkpoints are Bio-Techne shareholder approval, regulatory reviews, financing execution, and the closing window. The companies set the expected completion period at late 2026 or early 2027, which keeps deal-spread, antitrust, and integration risk in focus until approvals are secured.
Not investment advice. Verify all figures with primary sources before acting.
Related Articles
Jardine Matheson agreed to buy 100% of I-MED Radiology Network at an AUD3.4B ($2.4B) enterprise value. The price equals roughly 11.5x projected adjusted EBITDA for the year ending June 2026, with cash and debt funding and 2026 EPS guidance unchanged.
Eli Lilly agreed to acquire AtaiBeckley for $6.75 a share in cash, valuing the upfront consideration at about $2.8B. A CVR could add up to $2.50 a share, or about $1.0B, tied to BPL-003 and VLS-01 milestones.
Boeing $BA gained 8.03% to $233.49 after the FAA granted an amended type certificate for the 737-7 and BNP Paribas upgraded the stock by two notches. The regulatory approval clears another 737 MAX variant for commercial service after years of delay.